R W Sutter

Summary

Affiliation: World Health Organization
Country: Switzerland

Publications

  1. doi request reprint Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial
    Roland W Sutter
    World Health Organization, Geneva, Switzerland
    Lancet 376:1682-8. 2010
  2. ncbi request reprint Mass vaccination campaigns for polio eradication: an essential strategy for success
    R W Sutter
    Polio Eradication Initiative, World Health Organization, Geneva, Switzerland
    Curr Top Microbiol Immunol 304:195-220. 2006
  3. pmc The role of routine polio immunization in the post-certification era
    Roland W Sutter
    Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland
    Bull World Health Organ 82:31-9. 2004
  4. ncbi request reprint A global call for new polio vaccines
    David L Heymann
    Global Polio Eradication Initiative, World Health Organization, 20 Avenue Appia, CH 1211 Geneva, Switzerland
    Nature 434:699-700. 2005
  5. ncbi request reprint Risk management in a polio-free world
    R Bruce Aylward
    Global Polio Eradication Initiative, World Health Organization, Geneva, Switzerland
    Risk Anal 26:1441-8. 2006
  6. ncbi request reprint A vision of a world without polio: the OPV cessation strategy
    David L Heymann
    World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Biologicals 34:75-9. 2006
  7. ncbi request reprint Policy. OPV cessation--the final step to a "polio-free" world
    R Bruce Aylward
    Global Polio Eradication Initiative, World Health Organization, Geneva 27 Switzerland
    Science 310:625-6. 2005
  8. pmc Disease eradication as a public health strategy: a case study of poliomyelitis eradication
    R B Aylward
    Expanded Programme on Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland
    Bull World Health Organ 78:285-97. 2000
  9. doi request reprint Monovalent type 1 oral poliovirus vaccine in newborns
    Nasr El-Sayed
    Ministry of Health and Population, Cairo, Egypt
    N Engl J Med 359:1655-65. 2008
  10. doi request reprint Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management
    Radboud J Duintjer Tebbens
    Kids Risk Project, Harvard School of Public Health, Boston, MA 02115, USA
    Risk Anal 28:855-76. 2008

Collaborators

Detail Information

Publications26

  1. doi request reprint Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial
    Roland W Sutter
    World Health Organization, Geneva, Switzerland
    Lancet 376:1682-8. 2010
    ..Poliovirus types 1 and 3 co-circulate in poliomyelitis-endemic countries. We aimed to assess the immunogenicity of a novel bivalent types 1 and 3 oral poliovirus vaccine (bOPV)...
  2. ncbi request reprint Mass vaccination campaigns for polio eradication: an essential strategy for success
    R W Sutter
    Polio Eradication Initiative, World Health Organization, Geneva, Switzerland
    Curr Top Microbiol Immunol 304:195-220. 2006
    ..This chapter reviews the scientific, operational and programmatic data on mass campaign use of polio vaccines, and summarize the lessons learnt from implementing the mass vaccination strategies used to eradicate poliomyelitis globally...
  3. pmc The role of routine polio immunization in the post-certification era
    Roland W Sutter
    Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland
    Bull World Health Organ 82:31-9. 2004
    ..This report reviews the key issues associated with each scenario, highlights the advantages and disadvantages of each scenario, and outlines the major challenges for policy decision-making...
  4. ncbi request reprint A global call for new polio vaccines
    David L Heymann
    Global Polio Eradication Initiative, World Health Organization, 20 Avenue Appia, CH 1211 Geneva, Switzerland
    Nature 434:699-700. 2005
  5. ncbi request reprint Risk management in a polio-free world
    R Bruce Aylward
    Global Polio Eradication Initiative, World Health Organization, Geneva, Switzerland
    Risk Anal 26:1441-8. 2006
    ....
  6. ncbi request reprint A vision of a world without polio: the OPV cessation strategy
    David L Heymann
    World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
    Biologicals 34:75-9. 2006
    ..Final preparations for the eventual global and simultaneous cessation of OPV will require the same level of international cooperation and coordination that has brought the world to the verge of polio eradication...
  7. ncbi request reprint Policy. OPV cessation--the final step to a "polio-free" world
    R Bruce Aylward
    Global Polio Eradication Initiative, World Health Organization, Geneva 27 Switzerland
    Science 310:625-6. 2005
    ..This Policy Forum reviews the feasibility and implications of eventually stopping the use of live polio vaccines...
  8. pmc Disease eradication as a public health strategy: a case study of poliomyelitis eradication
    R B Aylward
    Expanded Programme on Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland
    Bull World Health Organ 78:285-97. 2000
    ..When the humanitarian, economic and consequent benefits of this initiative are measured against the costs, a strong argument is made for eradication as a valuable disease control strategy...
  9. doi request reprint Monovalent type 1 oral poliovirus vaccine in newborns
    Nasr El-Sayed
    Ministry of Health and Population, Cairo, Egypt
    N Engl J Med 359:1655-65. 2008
    ..Although substantial progress toward this goal has been made, eradication remains elusive. In 2004, the World Health Organization called for the development of a potentially more immunogenic monovalent type 1 oral poliovirus vaccine...
  10. doi request reprint Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management
    Radboud J Duintjer Tebbens
    Kids Risk Project, Harvard School of Public Health, Boston, MA 02115, USA
    Risk Anal 28:855-76. 2008
    ....
  11. pmc The risks, costs, and benefits of possible future global policies for managing polioviruses
    Kimberly M Thompson
    Kids Risk Project, Harvard School of Public Health, 677 Huntington Ave, Third Floor, Boston, MA 02115, USA
    Am J Public Health 98:1322-30. 2008
    ..We assessed the costs, risks, and benefits of possible future major policy decisions on vaccination, surveillance, response plans, and containment following global eradication of wild polioviruses...
  12. ncbi request reprint Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study
    Nicholas C Grassly
    Department of Infectious Disease Epidemiology, Imperial College London, London, UK
    Lancet 369:1356-62. 2007
    ..A high-potency monovalent oral type 1 poliovirus vaccine (mOPV1) was developed in 2005 to tackle persistent poliovirus transmission in the last remaining infected countries. Our aim was to assess the efficacy of this vaccine in India...
  13. ncbi request reprint Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling
    Kimberly M Thompson
    Kids Risk Project, Harvard School of Public Health, 677 Huntington Ave, 3rd Floor, Boston, MA 02115, USA
    Risk Anal 26:1571-80. 2006
    ..This analytical journey has provided several key insights and lessons learned that will be useful to future analysts involved in similar complex decision-making processes...
  14. ncbi request reprint Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication
    Radboud J Duintjer Tebbens
    Kids Risk Project, Harvard School of Public Health, Boston, MA, USA
    Risk Anal 26:1471-505. 2006
    ..This article attempts to comprehensively characterize the risks, synthesize the existing data available for modeling them, and present quantitative risk estimates that can provide a starting point for informing policy decisions...
  15. pmc Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine
    Kathryn A Kohler
    Global Immunization Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Bull World Health Organ 80:210-6. 2002
    ..Intensified OPV administration has reduced wild poliovirus transmission in India but VAPP is becoming a matter of concern...
  16. ncbi request reprint New strategies for the elimination of polio from India
    Nicholas C Grassly
    Department of Infectious Disease Epidemiology, Imperial College London, Norfolk Place, London, UK
    Science 314:1150-3. 2006
    ..We analyze strategies to counteract this and show that switching to monovalent vaccine may finally interrupt virus transmission...
  17. pmc Further clarity on vaccine-associated paralytic polio in India
    Kathryn A Kohler
    Bull World Health Organ 80:987. 2002
  18. ncbi request reprint Vaccine policy changes and epidemiology of poliomyelitis in the United States
    Lorraine Niño Alexander
    National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    JAMA 292:1696-701. 2004
    ..To reduce the VAPP burden, national vaccination policy changed in 1997 from reliance on OPV to options for a sequential schedule of inactivated poliovirus vaccine (IPV) followed by OPV. In 2000, an exclusive IPV schedule was adopted...
  19. ncbi request reprint Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis
    Nino Khetsuriani
    Respiratory and Enteric Viruses Branch, National Center for Infectious Diseases, and National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    J Infect Dis 188:1845-52. 2003
    ..These results are important for developing "endgame" strategies for the Global Poliomyelitis Eradication Program...
  20. ncbi request reprint A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future
    Radboud J Duintjer Tebbens
    KidsRisk Project, Harvard School of Public Health, Boston, MA 02115, USA
    Am J Epidemiol 162:358-72. 2005
    ..The authors expect that this model can provide important insights into the dynamics of future potential poliomyelitis outbreaks and in this way serve as a useful tool for risk assessment...
  21. ncbi request reprint Vaccine-derived polioviruses and the endgame strategy for global polio eradication
    Olen M Kew
    Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Annu Rev Microbiol 59:587-635. 2005
    ..Developing a posteradication strategy to minimize the risks of VDPV emergence and spread has become an urgent WHO priority...
  22. ncbi request reprint Outbreak of poliomyelitis due to type 3 poliovirus, northern India, 1999-2000: injections a major contributing factor
    Kathryn A Kohler
    Global Immunization Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Int J Epidemiol 32:272-7. 2003
    ..This raised concerns about oral poliovirus vaccine (OPV) effectiveness, particularly the type 3 component, in preventing clinical disease and offered an opportunity to describe the epidemiology of a P3 outbreak...
  23. pmc Compatible poliomyelitis cases in India during 2000
    Kathryn A Kohler
    Global Immunization Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Bull World Health Organ 81:2-9. 2003
    ..To describe the characteristics of compatible poliomyelitis cases and to assess the programmatic implications of clusters of such cases in India...
  24. pmc Polio control after certification: major issues outstanding
    Paul E M Fine
    London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, England
    Bull World Health Organ 82:47-52. 2004
    ..Given these important gaps in knowledge, no country should discontinue polio vaccination until a coordinated policy for the post-certification era has been developed and the recommended measures have been put in place...
  25. ncbi request reprint Survey of poliovirus antibodies during the final stage of polio eradication in Egypt
    Nasr El-Sayed
    Ministry of Health and Population MOHP, Cairo, Egypt
    Vaccine 25:5062-70. 2007
    ..Despite excellent program performance, wild poliovirus type 1 (PV1) continue to circulate in 2004. To investigate potential causes for the persistence, we conducted a serological study...
  26. ncbi request reprint IAP recommendations on Polio Eradication and Improvement of Routine Immunization
    Roland W Sutter
    Indian Pediatr 45:353-5. 2008